AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
CervoMed Inc.
Video analysis: CRVO
All videosNo video analysis for this stock yet. Request one from our team.
News: CRVO
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting
CervoMed to Participate in September Investor Conferences
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today announced that Company management will participate in the following investor conferences during the month of September:
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom's Innovative Licensing and Access Pathway (ILAP) for development in DLB New analyses presented at the Alzheimer's Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial Initial, 12-week biomarker data from Phase 2a clinical trial in nonfluent variant primary progressive aphasia (nfvPPA) to be presented at the 15 th International Conference on Frontotemporal Dementia (ISFTD) in October 2026; full 12-week and initial, 24-week biomarker data to be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in November 2026 Completed two equity financings in June 2026 for aggregate gross proceeds of approximately $20.5 million, extending cash runway through the third quarter of 2027 BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the second quarter ended June 30, 2026, and provided corporate updates. “The second quarter was marked by meaningful progress across both our business and pipeline.
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026. During the fireside chat, management will share recent progress in neflamapimod's clinical development program.
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as optimal dosing strategies
